Global Trends Overview: The Rapid Evolution of the Oral Solid Dosage Pharmaceutical Formulation Market

The oral solid dosage pharmaceutical formulation sector is on track for significant expansion as healthcare demands evolve. This segment of the pharmaceutical industry is expected to experience robust growth driven by innovations and shifting patient preferences, positioning it as a pivotal area in drug delivery and treatment options. Below is an overview of key market projections, influential companies, emerging trends, and detailed segmentation within this market.

Expected Expansion and Market Size of the Oral Solid Dosage Pharmaceutical Formulation Market
The oral solid dosage pharmaceutical formulation market is projected to reach a substantial size of $846.38 billion by 2030, growing steadily at a compound annual growth rate (CAGR) of 5.2%. This upward trajectory is fueled by a variety of factors including increased demand for long-acting oral medicines, greater emphasis on patient adherence and convenience, the growth of pharmaceutical outsourcing and contract development and manufacturing organizations (CDMOs), an uptick in generic drug manufacturing globally, and innovations in excipients and formulation technologies. Key market trends expected to dominate the forecast period include rising use of controlled and modified-release dosage forms, enhanced focus on patient-friendly oral solid formats, expansion of generic and branded solid dosage manufacturing, increased development of high-bioavailability formulations, and a shift toward scalable, cost-effective oral dosage production methods.

Download a free sample of the oral solid dosage pharmaceutical formulation market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15626&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Prominent Players Leading the Oral Solid Dosage Pharmaceutical Formulation Industry
Several leading companies play a crucial role in shaping the oral solid dosage pharmaceutical formulation market. These include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, and CordenPharma International.

Strategic Acquisition Reinforcing Market Position
In March 2024, France-based food company Roquette Frères made a strategic move by acquiring IFF Pharma Solutions for $2.85 billion. This acquisition strengthens Roquette's footprint in the pharmaceutical sector by broadening its product portfolio, enhancing its formulation expertise, and expanding its global reach. IFF Pharma Solutions, headquartered in the US, specializes in pharmaceutical products such as tablets and capsules, making this a significant addition to Roquette's capabilities in innovative drug delivery.

View the full oral solid dosage pharmaceutical formulation market report:
https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovations Driving Growth in Oral Solid Dosage Formulations
Leading companies in the oral solid dosage market are actively developing cutting-edge solutions like fixed dose combinations (FDCs) to improve treatment effectiveness, patient adherence, and safety profiles. FDCs combine two or more active pharmaceutical ingredients into a single dosage form, simplifying therapy and encouraging better compliance. For example, in February 2025, Ono Pharmaceutical Co. Ltd., based in Japan, secured FDA approval for Journavex (suzetrigine) 50 mg oral tablets aimed at treating moderate to severe acute pain in adults. This medication targets NaV1.8 sodium channels in the peripheral nervous system to block pain signals before they reach the brain, providing effective relief without the risk of addiction. Clinical trials have shown that Journavex significantly reduces pain compared to placebo, with only mild side effects such as itching and muscle spasms observed.

Comprehensive Segmentation of the Oral Solid Dosage Pharmaceutical Formulation Market
The oral solid dosage pharmaceutical formulation market is segmented into several categories for a detailed understanding:

Dosage Form:
- Tablets
- Capsules
- Powders and Granules
- Lozenges and Pastilles
- gummie*s*

Mechanism of Release:
- Controlled-Release
- Immediate-Release
- Delayed-Release

Distribution Channels:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
- Hypermarkets or Supermarkets

End-Users:
- Large-Size Companies
- Medium and Small-Size Companies
- Other End-Users

Further breakdown includes:
Tablets: Immediate-Release, Extended-Release, Controlled-Release, Effervescent, Chewable, Sublingual
Capsules: Hard Gelatin, Soft Gel, Liquid-Filled, Delayed-Release
Powders and Granules: Oral Powders (Reconstitution), Granules (Oral Suspension or Dispersible)
Lozenges and Pastilles: Medicinal, Herbal, Sugar-Free Lozenges, Pastilles for Throat or Cough Relief
gummie*s*: Vitamin, Herbal and Nutritional Supplements, Pharmaceutical gummie*s* for Pain Relief or Sleep Aids

This detailed segmentation highlights the breadth and diversity of products available in the oral solid dosage pharmaceutical formulation market, catering to various therapeutic needs and patient preferences.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.